A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.

@article{Delavenne2013ASA,
  title={A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.},
  author={Xavier Delavenne and Edouard Ollier and Thierry Basset and Laurent Bertoletti and Sandrine Accassat and Arnauld Garcin and Silvy Laporte and Paul Zufferey and Patrick Mismetti},
  journal={British journal of clinical pharmacology},
  year={2013},
  volume={76 1},
  pages={
          107-13
        }
}
AIM The aim of this study was to develop a PK/PD model to assess drug-drug interactions between dabigatran and P-gp modulators, using the example of clarithromycin, a strong inhibitor of P-gp. METHODS Ten healthy male volunteers were randomized to receive in the first treatment period a single 300 mg dose of dabigatran etexilate (DE) and in the second treatment period 500 mg clarithromycin twice daily during 3 days and then 300 mg DE plus 500 mg clarithromycin on the fourth day, or the same… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

RELY - genetics : genetic determinants of dabigatran plasma levels and their relation to clinical response

  • G Pare
  • Eur Heart J
  • 2012

RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation

  • HC, CD Joyner, L Wallentin
  • N Engl J Med
  • 2009

clavulanic acid

  • G. Pare
  • Fundam Clin Pharmacol
  • 2009

Similar Papers

Loading similar papers…